Trump Says Medicare Will Soon Cover Weight-Loss Drugs
by Aldgra Fredly via The Epoch Times,
President Donald Trump announced on May 1 that Medicare patients will soon be able to obtain coverage for weight-loss drugs for
# THE TAKE: Trump's Medicare Weight-Loss Gambit Is Corporate Capture, Full Stop Trump just handed Novo Nordisk and Eli Lilly a golden ticket disguised as healthcare policy. His May 1 announcement—Medicare covering GLP-1 drugs like Ozempic and Mounjaro—isn't compassion. It's regulatory capture dressed in populist rhetoric. Here's the receipts: These drugs cost $10,000+ annually. Medicare expansion means taxpayers subsidize pharma's obscene margins while the companies faced zero pressure on pricing. Trump's team negotiated *nothing* on cost, demanded *nothing* on transparency. Meanwhile, gastric bypass—proven, cheaper, durable—gets sidelined. Why? No $300-million lobbying budget. This isn't about helping obese seniors. It's about creating recurring revenue streams for pharmaceutical corporations while maintaining the illusion Trump fights Big Pharma. He doesn't. He just redistributes whose pockets get lined. Follow the money. Always.
What the Documents Show
The $50 monthly cap represents a substantial reduction from retail , which can exceed $900 per month for these drugs. However, the announcement raises questions about how this pricing was determined and what manufacturers agreed to in exchange for expanded Medicare access. The framework underlying this coverage expansion traces to December, when the Centers for Medicare & Medicaid Services (CMS) announced the Better Approaches to Lifestyle and Nutrition for Comprehensive Health model. This voluntary program allows Medicare Part D plans and state Medicaid agencies to negotiate directly with pharmaceutical manufacturers for reduced net prices. The model includes provisions for out-of-pocket caps, standardized coverage criteria, and lifestyle support programs.
Follow the Money
Notably, this represents CMS negotiating leverage over drug prices—a power previously limited under federal law. The timing of this announcement deserves scrutiny. While mainstream coverage frames this as patient-friendly policy, the agreement appears to concentrate significant purchasing power in federal hands while guaranteeing manufacturers access to millions of Medicare beneficiaries. GLP-1 drugs represent one of the fastest-growing pharmaceutical markets, with manufacturers reporting record demand. By bringing Medicare patients into the market at a negotiated price, the government simultaneously expands the customer base for these medications and potentially legitimizes their use for weight management rather than their original diabetes indication. The lifestyle support components embedded in the CMS model remain underspecified in available reporting.
What Else We Know
What constitutes these programs, who administers them, and whether they're mandatory for coverage eligibility remain unclear from the source material. These details matter significantly for understanding whether coverage represents genuine access expansion or creates new bureaucratic barriers for some Medicare beneficiaries. For ordinary Americans on Medicare, this policy creates immediate practical consequences. Seniors facing weight-related health conditions gain access to expensive medications previously out of reach. However, the $50 cap applies only through this voluntary model, meaning coverage varies by insurance plan and state Medicaid agency participation. Those enrolled in plans declining participation receive no benefit.
Primary Sources
- Source: ZeroHedge
- Category: Government Secrets
- Cross-reference independently — don't take our word for it.
Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.
This article is produced by NewsAnarchist's AI reporting system, not a human staff reporter. It's built from the primary source cited above (a declassified document, a FOIA release, an inspector general or congressional report, or a named whistleblower disclosure reported by outlets we cite) and reports what that source states, attributed to it — it reports what the document or disclosure states and does not speculate about what remains classified beyond that. Part of our Government Secrets hub. Found an error? Tell us.